FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Audeo Oncology's FCF Yield % or its related term are showing as below:
AURX's FCF Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: -0.55 * Ranked among companies with meaningful FCF Yield % only.
The historical data trend for Audeo Oncology's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Audeo Oncology FCF Yield % Chart
Audeo Oncology Annual Data
Trend
Jun10
Jun11
Jun12
FCF Yield %
-
-
-
Audeo Oncology Quarterly Data
Jun11
Mar12
Jun12
Sep12
FCF Yield %
-
-
-
-
Competitive Comparison of Audeo Oncology's FCF Yield %
For the Drug Manufacturers - General subindustry, Audeo Oncology's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Audeo Oncology's FCF Yield % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Audeo Oncology's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Audeo Oncology's FCF Yield % falls into.
Audeo Oncology FCF Yield % Calculation
FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Audeo Oncology's FCF Yield % for the fiscal year that ended in Jun. 2012 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Audeo Oncology FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Audeo Oncology FCF Yield % Related Terms
Thank you for viewing the detailed overview of Audeo Oncology's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Audeo Oncology (Audeo Oncology) Business Description
Audeo Oncology, Inc was incorporated in Delaware in June 2012. It is a late stage biopharmaceutical company utilizing its Hyaluronic Acid Chemotransport Technology, or HyACT, to target cancer drugs preferentially to tumor cells to enhance drug activity. HyACT is a flexible platform technology designed to increase the effectiveness of anti-cancer agents without increasing treatment toxicity. It seeks to reduce the risks related to drug development by using known anti-cancer drugs, and aim to enhance their commercial value by improving their effectiveness. The Company's lead HyACT product candidate, HA-Irinotecan, is currently in a pivotal Phase III clinical trial for metastatic colorectal cancer, or mCRC. HA-Irinotecan is also in an investigator-sponsored Phase II clinical trial for small cell lung cancer, or SCLC. It also has two other HyACT product candidates that have successfully completed Phase I clinical trials. In addition to its current clinical-stage product candidates, it aims to develop a pipeline of product candidates by exploiting its significant know-how in cancer stem cell biology and cancer metabolism combined with the Versatile Assembly on Stable Templates, or VAST, molecule drug discovery technology that it will in-license. The Company's lead product candidate is HyACT-targeted irinotecan, or HA-Irinotecan, for the treatment of mCRC. Irinotecan, which is marketed in major markets by Pfizer as Camptosar, is an off-patent chemotherapy drug widely used in the treatment of mCRC. Government authorities in the United States (including federal, state and local authorities) and in other countries extensively regulate the manufacture, research, clinical development, labeling, packaging, distribution, post-approval monitoring and reporting, advertising, promotion, export and import of pharmaceutical products, such as those it is developing.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DELISTED:AURX has been successfully added to your